The purpose of the emerging interdisciplinary science of regenerative medicine is to investigate new therapeutic methods and strategies for repairing, replacing, and regenerating human cells or tissues, with the aim of restoring functions that are impaired as a result of congenital defects, diseases, trauma, and aging. Infrastructure for research in regenerative medicine currently exists in Taiwan, and includes hardware and software facilities at many universities and medical centers; relevant laws/regulations are being revised. To promote the international competitiveness of regenerative medicine and stem cell therapy research in Taiwan, and to accelerate the progress of the biotech industry, the effective integration of different academic R&D teams with relevant industry chains is currently the most urgent task.
The program is designed to provide support for proposed projects of outstanding interdisciplinary teams, and will coordinate with the "5+2 Innovative Industries" policy to promote cross-field integration, which will seek to bring together Taiwan’s existing advantages in the areas of drug development, gene therapy, stem cell transplantation, tissue engineering, medical equipment, and smart devices for the purpose of building a solid foundation for future precision medicine. Through the formation of local innovation clusters and a global network for market expansion, under revised laws/regulations, human resources, capital, and intellectual property will be integrated in projects on carefully selected topics in an innovation-friendly environment, and fulfill the goals of the "Biomedical Industrial Innovation Promotion Program."
The program encourages outstanding researchers to form world-class teams dedicated to forward-looking research, talent cultivation, and the advancement of large-scale systemic technologies focusing on regenerative medicine. Research under the program should be translational, innovative, integrative, groundbreaking, and internationally competitive. The program includes the following major fields:
A. Integration of interdisciplinary technologies, such as drug development, gene therapy, stem cell applications, tissue engineering, and smart devices.
B. Partnership between industry and academia: Encouraging upstream academic institutions to form alliances with downstream companies and science parks.
C. New ventures or guidance for industrial transformation: Exploitation of Taiwan’s pre-existing advantages, such as through the cooperative development of bioreactors, tissue chips, precision medicine products, and high-value diagnostic devices in conjunction with the smart machinery industry.
D. Talent cultivation: Planning of on-the-job training, encouragement of increases in salary and employment rates, and cultivation of R&D talent possessing international competitiveness.
E. Ethical, legal, and social impact: Investigation of ethics, legal, and management rules in order to find methods of coping with critical issues connected with regenerative medicine research and stem cell therapy.
The Regenerative Medicine Program will help to promote research outputs in stem cells and regenerative medicine, as well as facilitate the industrialization of research results in Taiwan. The expected performance and success of this program will significantly enhance the training of multidisciplinary talent, promote international cooperation, and enable Taiwan to play a crucial role in the international healthcare market.